Skip to content
Pharma & Life Sciences 2025 Industry Outlook: Navigating Third-Party Risk in a Shifting Landscape
The pharmaceutical and life sciences industry faces unprecedented pressures: stricter regulations, rising ESG requirements, geopolitical volatility, and fragile supply chains. At the same time, third-party relationships—from contract manufacturers to logistics providers—are more critical than ever, but also a major source of risk exposure.
Ethixbase360’s Pharma Outlook Guidebook provides a clear view of what’s ahead and how to respond. Inside, you’ll find sector-specific insights on compliance and enforcement trends, practical strategies for managing third-party risks, and a roadmap for turning regulatory challenges into opportunities for resilience and growth.
The guide highlights:
Sector-specific vulnerabilities in globalized supply chains, data integrity, and ESG compliance.
Evolving regulations including the EU CSDDD, U.S. FEPA, and global forced labor import bans.
Practical strategies for building resilience—tiering suppliers, digitizing TPRM, embedding ESG standards, and leveraging automation with human intelligence.
The business case for strong TPRM: investor confidence, M&A readiness, operational agility, and brand protection.
This guide is designed to help compliance leaders strengthen third-party risk management, protect reputation, and build long-term value in a rapidly changing market.
